FDA Considers Easing Peptide Restrictions; Hims & Hers Stock Soars by 12%
Shares of telehealth giant, Hims & Hers Health, soared by over 12% this week, following a significant announcement by the U.S. Food and Drug Administration (FDA) that could potentially revolutionize the wellness peptide market.
On April 15, 2026, Health Secretary Robert F. Kennedy Jr. revealed that the FDA plans to convene a meeting in the summer to contemplate relaxing restrictions on more than a dozen peptide injections. These therapies, which have gained immense popularity among wellness influencers and fitness enthusiasts, are frequently touted as rapid solutions for muscle building, injury healing, and signs of aging reduction.
The FDA’s Pharmacy Compounding Advisory Committee is scheduled to meet on July 23-24 to assess whether seven peptide substances should be permitted for production by compounding pharmacies. An additional five peptides will undergo review before February 2027. Kennedy, a self-proclaimed “big fan” of peptides, stated that the initiative aims to curb black market activity and restore regulated access to these treatments.
For Hims & Hers, which purchased a peptide manufacturing facility in California in 2025, this regulatory shift could pave the way for substantial new revenue opportunities. Following the announcement, Bank of America elevated its price target for the company from $21 to $25. However, experts caution that the majority of peptides have not undergone safety reviews by the FDA, and the agency previously highlighted risks such as cancer and liver, kidney, and heart issues when it imposed restrictions on these substances in 2023.
Source: NBC News